Mark McKenna, Mirador Therapeutics CEO
March 21, 2024 07:00 AM EDT
Financing
Startups

For­mer Prometheus ex­ecs raise $400M for pre­ci­sion im­munol­o­gy start­up: 'The band is back to­geth­er'

Ryan Cross

Senior Science Correspondent

Af­ter sell­ing his last com­pa­ny to Mer­ck for $10.8 bil­lion in June, Mark McKen­na couldn’t shake the feel­ing that he’d left the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times